Skip to main content
Equibles
BNTC logo

BNTC · Benitec Biopharma Inc. · Investor Relations

Track BNTC — free

Use BNTC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BNTC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.54 +0.90 (+10.42%) At close · Nov 6
Russell 2000 member Rebalance outlook locked
Market Cap
$332.78M
Shares
34.88M
Volume · Nov 6 120.37K Avg daily vol (3M) 186.02K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-10-28 Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

Past events

Date Event Type
2026-10-28 Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Event
2026-10-05 Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study Event
2026-09-14 Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update Results publication
2026-05-14 Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update Results publication
2026-04-28 Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting Presentation
2026-03-10 Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) Conference
2026-03-09 Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference Conference
2026-02-23 Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference Conference
2026-02-12 Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update Results publication
2026-01-11 Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response Event
2025-11-14 Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update Results publication
2025-11-06 Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering Event
2025-11-05 Benitec Biopharma Inc. Announces Proposed Public Offering Event

Source: https://ir.benitec.com/

Key facts CIK 1808898 CUSIP 08205P209 13F (30d) 24 filings 24 filers Visit website Investor relations